drugset / Trial / NCT01421524

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

NCT01421524

Phase 1 Completed 271 enrolled Celgene Corporation
RandomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials.

Timeline

Start
2011-09-12
Primary completion
2023-11-21
Completion
2023-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Avadomide Other / unclassified 2 mg Oral
Subject Avadomide Other / unclassified 3 mg Oral
Subject Avadomide Other / unclassified 4 mg Oral
Subject Avadomide Other / unclassified 5 mg Oral
Subject Avadomide Other / unclassified 6 mg Oral